A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Sponsors Bristol-Myers Squibb; Ono Pharmaceutical

06 Jul 2023 Status changed from active, no longer recruiting to completed.
31 Oct 2022 Planned End Date changed from 14 Feb 2023 to 31 Oct 2023.
31 Oct 2022 Planned primary completion date changed from 12 Aug 2022 to 31 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com